ETR:SAZ STADA Arzneimittel Aktiengesellschaft (SAZ) Stock Price, News & Analysis €80.40 0.00 (0.00%) As of 11/27/2018 Add Compare Share Share Stock Analysis Stock Analysis About STADA Arzneimittel Aktiengesellschaft Stock (ETR:SAZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SAZ alerts:Sign Up Key Stats Today's Range€79.56▼€80.9850-Day Range€80.40▼€80.4052-Week Range€53.41▼€80.98Volume92,068 shsAverage Volume51,761 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSTADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.Read More… Receive SAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address SAZ Stock News HeadlinesCalliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyJuly 28, 2024 | stockhouse.comIPO/Kreise: Stada-Eigner bereden erneuten Börsengang und VerkaufsoptionenApril 11, 2024 | finanznachrichten.deHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orders. Among this blizzard of directives – ranging from slapping 25% tariffs on steel to banning the forced use of paper straws… Everyone seems to have missed the most important detail of all. February 22, 2025 | Porter & Company (Ad)IPO/Kreise: Stada-Eigner bereden erneuten Börsengang und VerkaufsoptionenApril 11, 2024 | finanznachrichten.deArzneihersteller Stada hat Russland-Geschäft abgespaltenDecember 27, 2023 | finanznachrichten.deBayerische Motoren Werke Aktiengesellschaft 2023 Q3 - Results - Earnings Call PresentationNovember 5, 2023 | seekingalpha.comBasler Aktiengesellschaft (ETR:BSL) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportApril 9, 2023 | finance.yahoo.comPTA-HV: Deutsche Real Estate Aktiengesellschaft: -3-April 6, 2023 | finanznachrichten.deSee More Headlines SAZ Stock Analysis - Frequently Asked Questions How have SAZ shares performed this year? STADA Arzneimittel Aktiengesellschaft's stock was trading at €80.40 at the start of the year. Since then, SAZ stock has increased by 0.0% and is now trading at €80.40. View the best growth stocks for 2025 here. What other stocks do shareholders of STADA Arzneimittel Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that STADA Arzneimittel Aktiengesellschaft investors own include ProSiebenSat.1 Media (PSM), Renault (RNO), Volkswagen Aktiengesellschaft (VLKAY), Volkswagen (VOW3), Andersons (ANDE), Nuwellis (CHFS) and Chemed (CHE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolETR:SAZ CUSIPN/A CIKN/A Webwww.stada.de Phone+49-6101-6030FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (ETR:SAZ) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding STADA Arzneimittel Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share STADA Arzneimittel Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.